ZA200204397B - Nitrile derivatives as cathepsin K inhibitors. - Google Patents

Nitrile derivatives as cathepsin K inhibitors.

Info

Publication number: ZA200204397B
Authority: ZA; South Africa
Prior art keywords: cathepsin; inhibitors; nitrile derivatives; nitrile; derivatives
Prior art date: 1999-12-24

Application number

ZA200204397A

Other languages

English (en)

Inventor

Tobias Gabriel

Sabine Wallbaum

Michael Pech

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-24

Filing date

2002-05-31

Publication date

2003-11-26

2002-05-31 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2003-11-26 Publication of ZA200204397B publication Critical patent/ZA200204397B/xx

Links

102000004171 Cathepsin K Human genes 0.000 title 1
108090000625 Cathepsin K Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
150000002825 nitriles Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ZA200204397A 1999-12-24 2002-05-31 Nitrile derivatives as cathepsin K inhibitors. ZA200204397B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99125857		1999-12-24

Publications (1)

Publication Number	Publication Date
ZA200204397B true ZA200204397B (en)	2003-11-26

Family

ID=8239727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200204397A ZA200204397B (en)	1999-12-24	2002-05-31	Nitrile derivatives as cathepsin K inhibitors.

Country Status (18)

Country	Link
US (1)	US6531612B2 (de)
EP (1)	EP1244621B1 (de)
JP (1)	JP3808772B2 (de)
KR (1)	KR100468254B1 (de)
CN (1)	CN1240681C (de)
AR (1)	AR027074A1 (de)
AT (1)	ATE339404T1 (de)
AU (1)	AU783145B2 (de)
BR (1)	BR0016699A (de)
CA (1)	CA2395179A1 (de)
CO (1)	CO5251410A1 (de)
DE (1)	DE60030768T2 (de)
ES (1)	ES2270898T3 (de)
MX (1)	MXPA02006163A (de)
PE (1)	PE20010984A1 (de)
UY (1)	UY26504A1 (de)
WO (1)	WO2001047886A1 (de)
ZA (1)	ZA200204397B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9723407D0 (en) *	1997-11-05	1998-01-07	Ciba Geigy Ag	Organic compounds
GB0003111D0 (en) *	2000-02-10	2000-03-29	Novartis Ag	Organic compounds
HUP0402344A2 (hu) *	2001-12-04	2005-02-28	F. Hoffmann-La Roche Ag	Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US7405234B2 (en) *	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
GB0220187D0 (en) *	2002-08-30	2002-10-09	Novartis Ag	Organic compounds
WO2004045518A2 (en) *	2002-11-15	2004-06-03	Bristol-Myers Squibb Company	Open chain prolyl urea-related modulators of androgen receptor function
US7256208B2 (en) *	2003-11-13	2007-08-14	Bristol-Myers Squibb Company	Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) *	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) *	2004-02-04	2005-08-18	Nirschl Alexandra A.	Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7696241B2 (en) *	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) *	2004-03-04	2008-06-17	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
EP1841730A4 (de) *	2005-01-19	2010-10-27	Merck Frosst Canada Ltd	Cathepsin-k-inhibitoren und atherosklerose
WO2007014839A2 (en) *	2005-07-27	2007-02-08	F. Hoffmann-La Roche Ag	Cathepsin k inhibitors
US20080227823A1 (en) *	2007-03-12	2008-09-18	Hassan Pajouhesh	Amide derivatives as calcium channel blockers
WO2008149971A1 (ja)	2007-06-08	2008-12-11	Kyoto University	脳動脈瘤の治療または予防薬
BRPI0813230A2 (pt) *	2007-06-28	2014-12-23	Novartis Ag	Moduladores de calicreína 7
KR100877394B1 (ko) *	2007-07-11	2009-01-07	한국화학연구원	카보니트릴 화합물을 포함하는 골다공증 및 치은 질환의치료 및 예방을 위한 약제학적 조성물
US20100331545A1 (en) *	2007-10-24	2010-12-30	Nippon Chemiphar Co., Ltd.	Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
US7902181B2 (en) *	2007-12-12	2011-03-08	Astrazeneca Ab	Compounds 010
EP2240491B1 (de)	2008-01-09	2015-07-15	Amura Therapeutics Limited	TETRAHYDROFURO(2,3-b)PYRROL-3-ON DERIVATE ALS INHIBITOREN VON CYSTEIN PROTEINASEN
CA2758210C (en) *	2009-04-20	2017-08-29	F. Hoffmann-La Roche Ag	Proline derivatives as cathepsin inhibitors
MX2011011661A (es)	2009-05-07	2011-11-18	Astrazeneca Ab	Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
US7893099B2 (en) *	2009-06-11	2011-02-22	Hoffman-La Roche Inc.	Cyclopentane derivatives
GB0913345D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	New combination 802
WO2011061527A1 (en)	2009-11-17	2011-05-26	Astrazeneca Ab	Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US8524710B2 (en) *	2010-11-05	2013-09-03	Hoffmann-La Roche Inc.	Pyrrolidine derivatives
GB201021992D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	Compound
GB201021979D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	New compound
EP2961403A4 (de)	2013-03-01	2016-11-30	Zalicus Pharmaceuticals Ltd	Heterocyclische inhibitoren des natriumkanals
EP2970252B1 (de) *	2013-03-14	2020-06-03	Boehringer Ingelheim International GmbH	Substituierte 2-aza-bicyclo[2.2.2]heptan-3-carboxylsäure(benzyl-cyan-methyl)-amid-hemmstoffe von cathepsin c
US20240336610A1 (en) *	2021-08-02	2024-10-10	The Global Health Drug Discovery Institute	3cl protease small-molecule inhibitor for treating or preventing coronavirus infection, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3606480A1 (de) *	1986-02-28	1987-09-03	Behringwerke Ag	Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
US4927909A (en)	1987-09-18	1990-05-22	Hoechst Celanese Corp.	Fabrication of high performance polybenzimidazole films
AU3359697A (en) *	1996-07-08	1998-02-02	Yamanouchi Pharmaceutical Co., Ltd.	Bone resorption inhibitors
US6015790A (en) *	1997-10-06	2000-01-18	Basf Aktiengesellschaft	Methods and compositions for treating rheumatoid arthritis
SK6572000A3 (en)	1997-11-05	2000-10-09	Novartis Ag	Dipeptide nitriles, process for the preparation thereof, their use as medicaments and pharmaceutical composition comprising them
DE60021254T2 (de) *	1999-03-15	2006-04-20	AXYS Pharmaceuticals, Inc., South San Francisco	N-cyanomethylamide als protease inhibitoren

2000
- 2000-12-13 ES ES00990733T patent/ES2270898T3/es not_active Expired - Lifetime
- 2000-12-13 CN CNB008175810A patent/CN1240681C/zh not_active Expired - Fee Related
- 2000-12-13 WO PCT/EP2000/012646 patent/WO2001047886A1/en not_active Ceased
- 2000-12-13 AT AT00990733T patent/ATE339404T1/de not_active IP Right Cessation
- 2000-12-13 CA CA002395179A patent/CA2395179A1/en not_active Abandoned
- 2000-12-13 MX MXPA02006163A patent/MXPA02006163A/es active IP Right Grant
- 2000-12-13 JP JP2001549358A patent/JP3808772B2/ja not_active Expired - Fee Related
- 2000-12-13 EP EP00990733A patent/EP1244621B1/de not_active Expired - Lifetime
- 2000-12-13 DE DE60030768T patent/DE60030768T2/de not_active Expired - Fee Related
- 2000-12-13 AU AU30106/01A patent/AU783145B2/en not_active Ceased
- 2000-12-13 BR BR0016699-5A patent/BR0016699A/pt not_active IP Right Cessation
- 2000-12-13 KR KR10-2002-7008003A patent/KR100468254B1/ko not_active Expired - Fee Related
- 2000-12-21 CO CO00097102A patent/CO5251410A1/es not_active Application Discontinuation
- 2000-12-21 PE PE2000001382A patent/PE20010984A1/es not_active Application Discontinuation
- 2000-12-21 US US09/745,675 patent/US6531612B2/en not_active Expired - Fee Related
- 2000-12-21 AR ARP000106868A patent/AR027074A1/es unknown
- 2000-12-22 UY UY26504A patent/UY26504A1/es not_active Application Discontinuation
2002
- 2002-05-31 ZA ZA200204397A patent/ZA200204397B/xx unknown

Also Published As

Publication number	Publication date
DE60030768D1 (en)	2006-10-26
CA2395179A1 (en)	2001-07-05
AU3010601A (en)	2001-07-09
CO5251410A1 (es)	2003-02-28
JP2003519125A (ja)	2003-06-17
PE20010984A1 (es)	2001-09-29
KR20020067559A (ko)	2002-08-22
EP1244621B1 (de)	2006-09-13
CN1413193A (zh)	2003-04-23
ES2270898T3 (es)	2007-04-16
KR100468254B1 (ko)	2005-01-27
UY26504A1 (es)	2001-06-29
US6531612B2 (en)	2003-03-11
MXPA02006163A (es)	2002-12-05
AR027074A1 (es)	2003-03-12
JP3808772B2 (ja)	2006-08-16
CN1240681C (zh)	2006-02-08
EP1244621A1 (de)	2002-10-02
AU783145B2 (en)	2005-09-29
BR0016699A (pt)	2002-11-05
DE60030768T2 (de)	2007-11-08
US20010008901A1 (en)	2001-07-19
ATE339404T1 (de)	2006-10-15
WO2001047886A1 (en)	2001-07-05

Publication	Publication Date	Title
ZA200204397B (en)	2003-11-26	Nitrile derivatives as cathepsin K inhibitors.
MXPA03005838A (es)	2003-09-10	Inhibidores de antigenos de aparicion muy tardia-4.
SI1686119T1 (sl)	2009-12-31	Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
ZA200108735B (en)	2003-01-23	Renin inhibitors.
MXPA03006250A (es)	2003-09-22	Compuestos heterociclicos terapeuticos.
ZA200202775B (en)	2004-02-25	Quinazoline derivatives as VEGF inhibitors.
ZA200109890B (en)	2003-02-26	Metalloprotease inhibitors.
MXPA03009647A (es)	2004-01-29	Heterociclildicarbamidas como inhibidores de caspasa.
ZA200307646B (en)	2004-07-13	Benzamidine derivative.
MXPA03001832A (es)	2003-06-04	Derivados de hidroxamato utiles como inhibidores de desacetilasa.
IL153484A0 (en)	2003-07-06	Colchinol derivatives as angiogenesis inhibitors
AU6623201A (en)	2002-02-05	Colchinol derivatives as angiogenesis inhibitors
AP2005003198A0 (en)	2005-03-31	Spiroindolinepiperidine derivatives.
ZA200500170B (en)	2006-02-22	Indole-3-sulphur derivatives.
AP2003002857A0 (en)	2003-09-30	New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
AU2002358700A8 (en)	2003-07-15	Urea derivatives as vr1- antagonists
ZA200108016B (en)	2003-03-26	Pyrazolobenzodiazephines as CDK2 inhibitors.
MXPA01013406A (es)	2003-09-04	Compuestos inhibidores de vla-4.
MXPA03006773A (es)	2003-10-24	Derivados de imidazol.
MXPA01011872A (es)	2003-09-04	Derivados de furanona como inhibidores de la catepsina s.
ZA200203095B (en)	2003-09-23	Biphenyl derivatives used as NHE-3 inhibitors.
MXPA02005067A (es)	2003-09-25	Composicion inhibidora de la corrosion.
MXPA03008140A (es)	2003-12-12	Amidas de acido benzofuran-2-carboxilico sustituidas.
ZA200408281B (en)	2005-10-14	Isoquinoline derivatives.
MXPA03005673A (es)	2003-10-06	Inhibidores de 8-arilquinolin-fosfodiesterasa-4-substituidos.